Artiva Biotherapeutics Inc ARTV
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2024-07-19 |
| Shares Out. | 48,590,000 |
| Website | artivabio.com/ ↗ |
| Phone | 18582674467 |
| Employees | 106 |
| Net Income | -$23.5M |
| Free Cash Flow | -$80.2M |
| Total Assets | $106.0M |
| Total Liabilities | $18.1M |
| Equity | $87.8M |
About Artiva Biotherapeutics Inc
Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials. The company pipeline includes AlloNK: is an allogeneic, off-the-shelf, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity (ADCC) effect of mAbs to drive B-cell. Others products includes: CAR-NK(AB201),CAR-NK(AB205).
Artiva Biotherapeutics Inc is a publicly traded company under the ticker symbol ARTV on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
12 analysts (2026-07-01)